Trial Profile
PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Jul 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Rituximab (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Obinutuzumab; Prednisolone; Vincristine
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms PETReA
- 15 Jun 2023 Results assessing Covid-19 vaccine responses in follicular lymphoma patients presented at the 28th Congress of the European Haematology Association
- 11 Oct 2022 Planned End Date changed from 1 Dec 2027 to 1 Dec 2029.
- 08 Jul 2022 Planned End Date changed from 1 Nov 2025 to 1 Dec 2027.